Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

NCT07092605 · Enrolling by invitation

Last updated 2026-05-28

This clinical trial is testing whether small doses of GLP-1 medications can help improve pain levels and overall well-being in adults.

Status Enrolling by invitation Only people invited by the researchers can join.

Phase Early Phase 1 First exploratory testing in people.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 150 people Planned (estimated).

Who can join Ages 18–65 · all sexes Healthy volunteers accepted.

Timeline Started 2024-11 · est. completion 2025-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07092605 ↗

Description as written by the study sponsor.

The goal of this clinical study has two objectives. The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity. The Secondary Objective: To assess the impact of these therapies on weight management practices and metabolic health.

Treatments tested

GLP-1 also known as Semaglutide Drug

Sublingual GLP1 (weekly), Subcutaneous GLP1 (weekly), Sublingual Placebo (weekly) for up to 6 months.
Placebo Drug

Sublingual Placebo (weekly) for up to 6 months

Main thing measured	Change in self-reported pain levels in participants microdosing GLP1s
Sponsor	AgelessRx
Conditions studied	Longevity, Quality of Life, Mood, Inflammation, Immune Health, Pain Management, Weight Management, Alertness
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07092605 ↗